NCT02894853View on ClinicalTrials.gov

Lung Cancer Early Molecular Assessment Trial

UnknownOBSERVATIONAL

Enrollment

1,297

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

GENETIC

Liquid (blood) biopsies and tumor biopsy (optional)

Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)

Trial Locations (1)

1066CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER